Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects

Advances in Cancer Research

Volumn 129, Issue , 2016, Pages 51-88

  Garg, Gaurav ^a   Khandelwal, Anuj ^a   Blagg, Brian S J ^a  

^a UNIVERSITY OF KANSAS   (United States)

Author keywords

Allosteric modulators; Cancer; Chaperone cycle; Client proteins; Heat shock response; Hsp90

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ANTINEOPLASTIC AGENT; BINDING PROTEIN; CELASTROL; CELL CYCLE PROTEIN 37; CHAPERONE; CISPLATIN; CRUENTAREN A; CYANOCOBALAMIN; DEGUELIN; DERRUBONE; EPIGALLOCATECHIN GALLATE; GAMBOGIC ACID; GEDUNIN; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; L 80; PACLITAXEL; PROTEIN P23; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; SANSALVAMIDE A; SILIBININ; UNCLASSIFIED DRUG; WITHAFERIN A; ADENOSINE TRIPHOSPHATE; ANTIOXIDANT; ENZYME INHIBITOR; ONCOPROTEIN; PROTEIN BINDING;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CARBOXY TERMINAL SEQUENCE; CELL CYCLE ARREST; CELL DISRUPTION; CELL ENERGY; CYTOTOXICITY; DRUG MECHANISM; DRUG STRUCTURE; HIGH THROUGHPUT SCREENING; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MOLECULARLY TARGETED THERAPY; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; STRUCTURE ACTIVITY RELATION; ALLOSTERISM; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; METABOLISM; NEOPLASMS; PROTEIN MULTIMERIZATION; PROTEIN TERTIARY STRUCTURE;

ADENOSINE TRIPHOSPHATE; ALLOSTERIC REGULATION; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; ENZYME INHIBITORS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; ONCOGENE PROTEINS; PROTEIN BINDING; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, TERTIARY; PROTEOLYSIS;

EID: 84957927619     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/bs.acr.2015.12.001     Document Type: Chapter

References (162)

1. Agarwal C., et al. Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells. Oncogene 2003, 22:8271-8282. 10.1038/sj.onc.1207158.
2. Alexander L.D., Partridge J.R., Agard D.A., McAlpine S.R. A small molecule that preferentially binds the closed conformation of Hsp90. Bioorganic & Medicinal Chemistry Letters 2011, 21:7068-7071. doi:10.1016/j.bmcl.2011.09.096.
3. Ali M.M.U., et al. Crystal structure of an Hsp90-nucleotide-p23/Sba1 closed chaperone complex. Nature 2006, 440:1013-1017. http://www.nature.com/nature/journal/v440/n7087/suppinfo/nature04716_S1.html.
4. Allison A.C., Cacabelos R., Lombardi V.R.M., Álvarez X.A., Vigo C. Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer's disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2001, 25:1341-1357. doi:10.1016/S0278-5846(01)00192-0.
5. Ardi V.C., Alexander L.D., Johnson V.A., McAlpine S.R. Macrocycles that inhibit the binding between heat shock protein 90 and TPR-containing proteins. ACS Chemical Biology 2011, 6:1357-1366. 10.1021/cb200203m.
6. Bagatell R., Whitesell L. Altered Hsp90 function in cancer: A unique therapeutic opportunity. Molecular Cancer Therapeutics 2004, 3:1021-1030.
7. Belofsky G.N., Jensen P.R., Fenical W. Sansalvamide: A new cytotoxic cyclic depsipeptide produced by a marine fungus of the genus Fusarium. Tetrahedron Letters 1999, 40:2913-2916. doi:10.1016/S0040-4039(99)00393-7.
8. Bhat R., et al. Structure-activity studies of (-)-epigallocatechin gallate derivatives as HCV entry inhibitors. Bioorganic & Medicinal Chemistry Letters 2014, 24:4162-4165. doi:10.1016/j.bmcl.2014.07.051.
9. Blagg B.S.J., Kerr T.D. Hsp90 inhibitors: Small molecules that transform the Hsp90 protein folding machinery into a catalyst for protein degradation. Medicinal Research Reviews 2006, 26:310-338. 10.1002/med.20052.
10. Brandt G.E., Blagg B.S. Alternate strategies of Hsp90 modulation for the treatment of cancer and other diseases. Current Topics in Medicinal Chemistry 2009, 9:1447-1461.
11. Brandt G.E.L., Schmidt M.D., Prisinzano T.E., Blagg B.S.J. Gedunin, a novel Hsp90 inhibitor: Semisynthesis of derivatives and preliminary structure-activity relationships. Journal of Medicinal Chemistry 2008, 51:6495-6502. 10.1021/jm8007486.
12. Burlison J.A., Neckers L., Smith A.B., Maxwell A., Blagg B.S.J. Novobiocin: Redesigning a DNA gyrase inhibitor for selective inhibition of Hsp90. Journal of the American Chemical Society 2006, 128:15529-15536. 10.1021/ja065793p.
13. Burlison J.A., et al. Development of novobiocin analogues that manifest anti-proliferative activity against several cancer cell lines. The Journal of Organic Chemistry 2008, 73:2130-2137. 10.1021/jo702191a.
14. Byrd C.A., et al. Heat shock protein 90 mediates macrophage activation by Taxol and bacterial lipopolysaccharide. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:5645-5650. 10.1073/pnas.96.10.5645.
15. Caboni P., et al. Rotenone, deguelin, their metabolites, and the rat model of Parkinson's disease. Chemical Research in Toxicology 2004, 17:1540-1548. 10.1021/tx049867r.
16. Caplan A.J., Mandal A.K., Theodoraki M.A. Molecular chaperones and protein kinase quality control. Trends in Cell Biology 2007, 17:87-92. 10.1016/j.tcb.2006.12.002.
17. Carroll C.L., et al. Synthesis and cytotoxicity of novel sansalvamide A derivatives. Organic Letters 2005, 7:3481-3484. 10.1021/ol051161g.
18. Chadli A., et al. Celastrol inhibits Hsp90 chaperoning of steroid receptors by inducing fibrillization of the co-chaperone p23. Journal of Biological Chemistry 2010, 285:4224-4231. 10.1074/jbc.M109.081018.
19. Chang D.-J., et al. Design, synthesis, and biological evaluation of novel deguelin-based heat shock protein 90 (HSP90) inhibitors targeting proliferation and angiogenesis. Journal of Medicinal Chemistry 2012, 55:10863-10884. 10.1021/jm301488q.
20. Chaudhury S., Welch T.R., Blagg B.S.J. Hsp90 as a target for drug development. ChemMedChem 2006, 1:1331-1340. 10.1002/cmdc.200600112.
21. Chen M., Rose A.E., Doudican N., Osman I., Orlow S.J. Celastrol synergistically enhances temozolomide cytotoxicity in melanoma cells. Molecular Cancer Research 2009, 7:1946-1953. 10.1158/1541-7786.MCR-09-0243.
22. Chi Y., et al. An open-labeled, randomized, multicenter phase IIa study of gambogic acid injection for advanced malignant tumors. Chinese Medical Journal 2013, 126:1642-1646.
23. Chiosis G., Neckers L. Tumor selectivity of Hsp90 inhibitors: The explanation remains elusive. ACS Chemical Biology 2006, 1:279-284. 10.1021/cb600224w.
24. Chiosis G., et al. 17AAG: Low target binding affinity and potent cell activity-Finding an explanation. Molecular Cancer Therapeutics 2003, 2:123-129.
25. Davenport J., et al. Gambogic acid, a natural product inhibitor of Hsp90. Journal of Natural Products 2011, 74:1085-1092. 10.1021/np200029q.
26. Davis M.R., et al. Synthesis of sansalvamide A peptidomimetics: Triazole, oxazole, thiazole, and pseudoproline containing compounds. Tetrahedron 2012, 68:1029-1051. doi:10.1016/j.tet.2011.11.089.
27. Ding A.H., Porteu F., Sanchez E., Nathan C.F. Shared actions of endotoxin and taxol on TNF receptors and TNF release. Science 1990, 248:370-372.
28. Ding A., Sanchez E., Nathan C.F. Taxol shares the ability of bacterial lipopolysaccharide to induce tyrosine phosphorylation of microtubule-associated protein kinase. The Journal of Immunology 1993, 151:5596-5602.
29. Donnelly A., Blagg B.S.J. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket. Current Medicinal Chemistry 2008, 15:2702-2717. 10.2174/092986708786242895.
30. Donnelly A.C., Zhao H., Reddy Kusuma B., Blagg B.S.J. Cytotoxic sugar analogues of an optimized novobiocin scaffold. Medicinal Chemistry Communications 2010, 1:165-170. 10.1039/C0MD00063A.
31. Donnelly A.C., et al. The design, synthesis, and evaluation of coumarin ring derivatives of the novobiocin scaffold that exhibit antiproliferative activity. The Journal of Organic Chemistry 2008, 73:8901-8920. 10.1021/jo801312r.
32. Duan H., et al. Triterpenoids from Tripterygium wilfordii. Phytochemistry 2000, 53:805-810.
33. Dutta R., Inouye M. GHKL, an emergent ATPase/kinase superfamily. Trends in Biochemical Sciences 2000, 25:24-28.
34. East A.J., Ollis W.D., Wheeler R.E. Natural occurrence of 3-aryl-4-hydroxycoumarins. Part I. Phytochemical examination of Derris robusta (roxb.) benth. Journal of the Chemical Society C: Organic 1969, 365-374. 10.1039/J39690000365.
35. Eskew J.D., et al. Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells. BMC Cancer 2011, 11:468. 10.1186/1471-2407-11-468.
36. Falsey R.R., et al. Actin microfilament aggregation induced by withaferin A is mediated by annexin II. Nature Chemical Biology 2006, 2:33-38. 10.1038/nchembio755.
37. Galam L., et al. High-throughput assay for the identification of Hsp90 inhibitors based on Hsp90-dependent refolding of firefly luciferase. Bioorganic & Medicinal Chemistry 2007, 15:1939-1946. doi:10.1016/j.bmc.2007.01.004.
38. Galanski M. Recent developments in the field of anticancer platinum complexes. Recent Patents on Anti-Cancer Drug Discovery 2006, 1:285-295.
39. Garg G., Zhao H., Blagg B.S.J. Design, synthesis, and biological evaluation of ring-constrained novobiocin analogues as Hsp90 C-terminal inhibitors. ACS Medical Chemistry Letters 2015, 6:204-209. 10.1021/ml5004475.
40. Gazak R., Walterova D., Kren V. Silybin and silymarin-New and emerging applications in medicine. Current Medicinal Chemistry 2007, 14:315-338.
41. Ghosh S., et al. Hsp90 C-terminal inhibitors exhibit antimigratory activity by disrupting the Hsp90α/Aha1 complex in PC3-MM2 cells. ACS Chemical Biology 2015, 10:577-590. 10.1021/cb5008713.
42. Gu W., Liu S.S., Silverman R.B. Solid-phase, Pd-catalyzed silicon-aryl carbon bond formation. Synthesis of sansalvamide A peptide. Organic Letters 2002, 4:4171-4174.
43. Gu M., et al. Structure-activity relationship (SAR) of withanolides to inhibit Hsp90 for its activity in pancreatic cancer cells. Investigational New Drugs 2014, 32:68-74. 10.1007/s10637-013-9987-y.
44. Hadden M.K., Galam L., Gestwicki J.E., Matts R.L., Blagg B.S.J. Derrubone, an inhibitor of the Hsp90 protein folding machinery. Journal of Natural Products 2007, 70:2014-2018. 10.1021/np070190s.
45. Hall J.A., Forsberg L.K., Blagg B.S. Alternative approaches to Hsp90 modulation for the treatment of cancer. Future Medicinal Chemistry 2014, 6:1587-1605. 10.4155/fmc.14.89.
46. Hall J.A., Kusuma B.R., Brandt G.E.L., Blagg B.S.J. Cruentaren A binds F1F0 ATP synthase to modulate the Hsp90 protein folding machinery. ACS Chemical Biology 2014, 9:976-985. 10.1021/cb400906e.
47. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70. doi:10.1016/S0092-8674(00)81683-9.
48. Hanahan D., Weinberg Robert A. Hallmarks of cancer: The next generation. Cell 2011, 144:646-674.
49. Hastings J.M., Hadden M.K., Blagg B.S.J. Synthesis and evaluation of derrubone and select analogues. The Journal of Organic Chemistry 2008, 73:369-373. 10.1021/jo702366g.
50. Hieronymus H., et al. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell 2006, 10:321-330. 10.1016/j.ccr.2006.09.005.
51. Hong D.S., et al. Targeting the molecular chaperone heat shock protein 90 (HSP90): Lessons learned and future directions. Cancer Treatment Reviews 2013, 39:375-387. doi:10.1016/j.ctrv.2012.10.001.
52. Huai Q., et al. Structures of the N-terminal and middle domains of E. coli Hsp90 and conformation changes upon ADP binding. Structure 2005, 13:579-590. doi:10.1016/j.str.2004.12.018.
53. Itoh H., et al. A novel chaperone-activity-reducing mechanism of the 90-kDa molecular chaperone HSP90. Biochemical Journal 1999, 343(Pt. 3):697-703.
54. Jhaveri K., Taldone T., Modi S., Chiosis G. Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochimica et Biophysica Acta 2012, 1823:742-755. 10.1016/j.bbamcr.2011.10.008.
55. Jolly C., Morimoto R.I. Role of the heat shock response and molecular chaperones in oncogenesis and cell death. Journal of the National Cancer Institute 2000, 92:1564-1572. 10.1093/jnci/92.19.1564.
56. Jordan P., Carmo-Fonseca M. Molecular mechanisms involved in cisplatin cytotoxicity. Cellular and Molecular Life Sciences: CMLS 2000, 57:1229-1235. 10.1007/PL00000762.
57. Kaileh M., et al. Withaferin A strongly elicits IκB kinase β hyperphosphorylation concomitant with potent inhibition of its kinase activity. Journal of Biological Chemistry 2007, 282:4253-4264. 10.1074/jbc.M606728200.
58. Kamal A., et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003, 425:407-410. http://www.nature.com/nature/journal/v425/n6956/suppinfo/nature01913_S1.html.
59. Kamath S.G., et al. Gedunin, a novel natural substance, inhibits ovarian cancer cell proliferation. International Journal of Gynecological Cancer 2009, 19:1564-1569. 10.1111/IGC.0b013e3181a83135.
60. Kannaiyan R., et al. Celastrol inhibits tumor cell proliferation and promotes apoptosis through the activation of c-Jun N-terminal kinase and suppression of PI3 K/Akt signaling pathways. Apoptosis 2011, 16:1028-1041. 10.1007/s10495-011-0629-6.
61. Khalid S., Paul S. Identifying a C-terminal ATP binding sites-based novel Hsp90-Inhibitor in silico: A plausible therapeutic approach in Alzheimer's disease. Medical Hypotheses 2014, 83:39-46. doi:10.1016/j.mehy.2014.04.013.
62. Khandelwal A., Crowley V.M., Blagg B.S. Natural product inspired N-terminal Hsp90 inhibitors: From bench to bedside?. Medicinal Research Reviews 2016, 36:92-118. 10.1002/med.21351.
63. Khandelwal A., Hall J.A., Blagg B.S.J. Synthesis and structure-activity relationships of EGCG analogues, a recently identified Hsp90 inhibitor. The Journal of Organic Chemistry 2013, 78:7859-7884. 10.1021/jo401027r.
64. Koay Y.C., et al. Chemically accessible hsp90 inhibitor that does not induce a heat shock response. ACS Medicinal Chemistry Letters 2014, 5:771-776. 10.1021/ml500114p.
65. Koga F., Kihara K., Neckers L. Inhibition of cancer invasion and metastasis by targeting the molecular chaperone heat-shock protein 90. Anticancer Research 2009, 29:797-807.
66. Kosano H., Stensgard B., Charlesworth M.C., McMahon N., Toft D. The assembly of progesterone receptor-hsp90 complexes using purified proteins. Journal of Biological Chemistry 1998, 273:32973-32979. 10.1074/jbc.273.49.32973.
67. Kunicki J.B., et al. Synthesis and evaluation of biotinylated sansalvamide A analogs and their modulation of Hsp90. Bioorganic & Medicinal Chemistry Letters 2011, 21:4716-4719. doi:10.1016/j.bmcl.2011.06.083.
68. Kunze B., Sasse F., Wieczorek H., Huss M. Cruentaren A, a highly cytotoxic benzolactone from Myxobacteria is a novel selective inhibitor of mitochondrial F1-ATPases. FEBS Letters 2007, 581:3523-3527. 10.1016/j.febslet.2007.06.069.
69. Kunze B., et al. Cruentaren, a new antifungal salicylate-type macrolide from Byssovorax cruenta (myxobacteria) with inhibitory effect on mitochondrial ATPase activity. Fermentation and biological properties. The Journal of Antibiotics 2006, 59:664-668. 10.1038/ja.2006.89.
70. Kvardova V., et al. The new platinum(IV) derivative LA-12 shows stronger inhibitory effect on Hsp90 function compared to cisplatin. Molecular Cancer 2010, 9:147. 10.1186/1476-4598-9-147.
71. Lamb J., et al. The Connectivity Map: Using gene-expression signatures to connect small molecules, genes, and disease. Science 2006, 313:1929-1935. 10.1126/science.1132939.
72. Lee S.C., et al. Synthesis and evaluation of a novel deguelin derivative, L80, which disrupts ATP binding to the C-terminal domain of heat shock protein 90. Molecular Pharmacology 2015, 88:245-255. 10.1124/mol.114.096883.
73. Li J., Soroka J., Buchner J. The Hsp90 chaperone machinery: Conformational dynamics and regulation by co-chaperones. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 2012, 624-635. doi:10.1016/j.bbamcr.2011.09.003.
74. Liu Z., Ma L., Zhou G.B. The main anticancer bullets of the Chinese medicinal herb, thunder god vine. Molecules 2011, 16:5283-5297. 10.3390/molecules16065283.
75. Liu Y., et al. Triptolide inhibits cell growth and induces G0-G1 arrest by regulating P21wap1/cip1 and P27 kip1 in human multiple myeloma RPMI-8226 cells. Chinese Journal of Cancer Research 2010, 22:141-147. 10.1007/s11670-010-0141-5.
76. Liu W., et al. KU675, a concomitant heat-shock protein inhibitor of Hsp90 and Hsc70 that manifests isoform selectivity for Hsp90alpha in prostate cancer cells. Molecular Pharmacology 2015, 88:121-130. 10.1124/mol.114.097303.
77. Logue J.S., Morrison D.K. Complexity in the signaling network: Insights from the use of targeted inhibitors in cancer therapy. Genes and Development 2012, 26:641-650. 10.1101/gad.186965.112.
78. Luo W., Sun W., Taldone T., Rodina A., Chiosis G. Heat shock protein 90 in neurodegenerative diseases. Molecular Neurodegeneration 2010, 5:24.
79. Marcu M.G., Chadli A., Bouhouche I., Catelli M., Neckers L.M. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. Journal of Biological Chemistry 2000, 275:37181-37186. 10.1074/jbc.M003701200.
80. Marcu M.G., Schulte T.W., Neckers L. Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins. Journal of the National Cancer Institute 2000, 92:242-248. 10.1093/jnci/92.3.242.
81. Mays J.R., Hill S.A., Moyers J.T., Blagg B.S.J. The synthesis and evaluation of flavone and isoflavone chimeras of novobiocin and derrubone. Bioorganic & Medicinal Chemistry 2010, 18:249-266. doi:10.1016/j.bmc.2009.10.061.
82. McConnell J.R., Alexander L.A., McAlpine S.R. A heat shock protein 90 inhibitor that modulates the immunophilins and regulates hormone receptors without inducing the heat shock response. Bioorganic & Medicinal Chemistry Letters 2014, 24:661-666. doi:10.1016/j.bmcl.2013.11.059.
83. Meyer P., et al. Structural and functional analysis of the middle segment of Hsp90: Implications for ATP hydrolysis and client protein and cochaperone interactions. Molecular Cell 2003, 11:647-658. doi:10.1016/S1097-2765(03)00065-0.
84. Mishra L.C., Singh B.B., Dagenais S. Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): A review. Alternative Medicine Review 2000, 5:334-346.
85. Mohan R., et al. Withaferin A is a potent inhibitor of angiogenesis. Angiogenesis 2004, 7:115-122. 10.1007/s10456-004-1026-3.
86. Murphy P.J.M., Kanelakis K.C., Galigniana M.D., Morishima Y., Pratt W.B. Stoichiometry, abundance, and functional significance of the hsp90/hsp70-based multiprotein chaperone machinery in reticulocyte lysate. Journal of Biological Chemistry 2001, 276:30092-30098. 10.1074/jbc.M103773200.
87. Nagase M., et al. Apoptosis induction in HL-60 cells and inhibition of topoisomerase II by triterpene celastrol. Bioscience, Biotechnology, and Biochemistry 2003, 67:1883-1887.
88. Neckers L., Workman P. Hsp90 molecular chaperone inhibitors: Are we there yet?. Clinical Cancer Research 2012, 18:64-76. 10.1158/1078-0432.ccr-11-1000.
89. Oh S.H., et al. Structural basis for depletion of heat shock protein 90 client proteins by deguelin. Journal of the National Cancer Institute 2007, 99:949-961. 10.1093/jnci/djm007.
90. Palermo C.M., Westlake C.A., Gasiewicz T.A. Epigallocatechin gallate inhibits aryl hydrocarbon receptor gene transcription through an indirect mechanism involving binding to a 90 kDa heat shock protein. Biochemistry 2005, 44:5041-5052. 10.1021/bi047433p.
91. Panaretou B., et al. ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo. EMBO Journal 1998, 17:4829-4836. 10.1093/emboj/17.16.4829.
92. Pandey M.K., et al. Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-kappaB signaling pathway. Blood 2007, 110:3517-3525. 10.1182/blood-2007-03-079616.
93. Papathanassiu A.E., MacDonald N.J., Bencsura A., Vu H.A. F1F0-ATP synthase functions as a co-chaperone of Hsp90-substrate protein complexes. Biochemical and Biophysical Research Communications 2006, 345:419-429. 10.1016/j.bbrc.2006.04.104.
94. Patel P.D., et al. Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2. Nature Chemical Biology 2013, 9:677-684. http://www.nature.com/nchembio/journal/v9/n11/abs/nchembio.1335.html, supplementary-information (2013). 10.1038/nchembio.1335.
95. Patwardhan C.A., et al. Gedunin inactivates the co-chaperone p23 protein causing cancer cell death by apoptosis. Journal of Biological Chemistry 2013, 288:7313-7325. 10.1074/jbc.M112.427328.
96. Paul S., Mahanta S. Association of heat-shock proteins in various neurodegenerative disorders: Is it a master key to open the therapeutic door?. Molecular and Cellular Biochemistry 2014, 386:45-61. 10.1007/s11010-013-1844-y.
97. Pearl L.H., Prodromou C. Structure and mechanism of the Hsp90 molecular chaperone machinery. Annual Review of Biochemistry 2006, 75:271-294. 10.1146/annurev.biochem.75.103004.142738.
98. Peterson L.B., Blagg B.S.J. To fold or not to fold: Modulation and consequences of Hsp90 inhibition. Future Medicinal Chemistry 2009, 1:267-283. 10.4155/Fmc.09.17.
99. Peterson L.B., Eskew J.D., Vielhauer G.A., Blagg B.S.J. The hERG channel is dependent upon the Hsp90α isoform for maturation and trafficking. Molecular Pharmaceutics 2012, 9:1841-1846. 10.1021/mp300138n.
100. Piaz F.D., Terracciano S., De Tommasi N., Braca A. Hsp90 activity modulation by plant secondary metabolites. Planta Medica 2015, 81:1223-1239. 10.1055/s-0035-1546251.
101. Prodromou C., et al. Regulation of Hsp90 ATPase activity by tetratricopeptide repeat (TPR)-domain co-chaperones. EMBO Journal 1999, 18:754-762. 10.1093/emboj/18.3.754.
102. Prodromou C., et al. The ATPase cycle of Hsp90 drives a molecular 'clamp' via transient dimerization of the N-terminal domains. The EMBO Journal 2000, 19:4383-4392.
103. Qin Y., et al. Gambogic acid inhibits the catalytic activity of human topoisomerase IIalpha by binding to its ATPase domain. Molecular Cancer Therapeutics 2007, 6:2429-2440. 10.1158/1535-7163.MCT-07-0147.
104. Ramsey D.M., et al. An Hsp90 modulator that exhibits a unique mechanistic profile. Bioorganic and Medicinal Chemistry Letters 2012, 22:3287-3290. 10.1016/j.bmcl.2012.03.012.
105. Ren Y., et al. Absolute configuration of (-)-gambogic acid, an antitumor agent. Journal of Natural Products 2011, 74:460-463. 10.1021/np100422z.
106. Riebold M., et al. A C-terminal HSP90 inhibitor restores glucocorticoid sensitivity and relieves a mouse allograft model of Cushing disease. Nature Medicine 2015, 21:276-280. 10.1038/nm.3776.
107. Rodriguez R.A., et al. Synthesis of second-generation sansalvamide A derivatives: Novel templates as potential antitumor agents. Journal of Organic Chemistry 2007, 72:1980-2002. 10.1021/jo061830j.
108. Rosenhagen M.C., et al. The heat shock protein 90-targeting drug cisplatin selectively inhibits steroid receptor activation. Molecular Endocrinology 2003, 17:1991-2001. 10.1210/me.2003-0141.
109. Salminen A., Lehtonen M., Paimela T., Kaarniranta K. Celastrol: Molecular targets of thunder god vine. Biochemical and Biophysical Research Communications 2010, 394:439-442. doi:10.1016/j.bbrc.2010.03.050.
110. Samadi A.K., et al. A novel C-terminal HSP90 inhibitor KU135 induces apoptosis and cell cycle arrest in melanoma cells. Cancer Letters 2011, 312:158-167. doi:10.1016/j.canlet.2011.07.031.
111. Sellers R.P., et al. Design and synthesis of Hsp90 inhibitors: Exploring the SAR of Sansalvamide A derivatives. Bioorganic & Medicinal Chemistry 2010, 18:6822-6856. doi:10.1016/j.bmc.2010.07.042.
112. Sethi G., Ahn K.S., Pandey M.K., Aggarwal B.B. Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-kappaB-regulated gene products and TAK1-mediated NF-kappaB activation. Blood 2007, 109:2727-2735. 10.1182/blood-2006-10-050807.
113. Shelton S.N., et al. KU135, a novel novobiocin-derived C-terminal inhibitor of the 90-kDa heat shock protein, exerts potent antiproliferative effects in human leukemic cells. Molecular Pharmacology 2009, 76:1314-1322. 10.1124/mol.109.058545.
114. Shohat B., Gitter S., Abraham A., Lavie D. Antitumor activity of withaferin A (NSC-101088). Cancer Chemotherapy Reports 1967, 51:271-276.
115. Sidera K., Patsavoudi E. Extracellular HSP90: Conquering the cell surface. Cell Cycle 2008, 7:1564-1568.
116. Solit D.B., Basso A.D., Olshen A.B., Scher H.I., Rosen N. Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Research 2003, 63:2139-2144.
117. Söti C., Rácz A., Csermely P. A nucleotide-dependent molecular switch controls ATP binding at the C-terminal domain of Hsp90: N-terminal nucleotide binding unmasks a C-terminal binding pocket. Journal of Biological Chemistry 2002, 277:7066-7075. 10.1074/jbc.M105568200.
118. Soti C., Vermes Á., Haystead T.A.J., Csermely P. Comparative analysis of the ATP-binding sites of Hsp90 by nucleotide affinity cleavage: A distinct nucleotide specificity of the C-terminal ATP-binding site. European Journal of Biochemistry 2003, 270:2421-2428. 10.1046/j.1432-1033.2003.03610.x.
119. Sreedhar A.S., Soti C., Csermely P. Inhibition of Hsp90: A new strategy for inhibiting protein kinases. Biochimica et Biophysica Acta 2004, 1697:233-242. 10.1016/j.bbapap.2003.11.027.
120. Sreeramulu S., Gande S.L., Göbel M., Schwalbe H. Molecular mechanism of inhibition of the human protein complex Hsp90-Cdc37, a kinome chaperone-cochaperone, by triterpene celastrol. Angewandte Chemie, International Edition 2009, 48:5853-5855. 10.1002/anie.200900929.
121. Srinivasan S., Ranga R.S., Burikhanov R., Han S.S., Chendil D. Par-4-dependent apoptosis by the dietary compound withaferin A in prostate cancer cells. Cancer Research 2007, 67:246-253. 10.1158/0008-5472.CAN-06-2430.
122. Taipale M., Jarosz D.F., Lindquist S. HSP90 at the hub of protein homeostasis: Emerging mechanistic insights. Nature Reviews. Molecular Cell Biology 2010, 11:515-528.
123. Taipale M., et al. Quantitative analysis of Hsp90-client interactions reveals principles of substrate recognition. Cell 2012, 150:987-1001. doi:10.1016/j.cell.2012.06.047.
124. Tao X., Lipsky P.E. The Chinese anti-inflammatory and immunosuppressive herbal remedy Tripterygium wilfordii Hook F. Rheumatic Diseases Clinics of North America 2000, 26:29-50. viii.
125. Trepel J., Mollapour M., Giaccone G., Neckers L. Targeting the dynamic HSP90 complex in cancer. Nature Reviews. Cancer 2010, 10:537-549. 10.1038/nrc2887.
126. Uddin S.J., et al. Gedunin, a limonoid from Xylocarpus granatum, inhibits the growth of CaCo-2 colon cancer cell line in vitro. Phytotherapy Research 2007, 21:757-761. 10.1002/ptr.2159.
127. Vartholomaiou E., Echeverría P.C., Picard D. Unusual suspects in the twilight zone between the Hsp90 interactome and carcinogenesis. Advances in Cancer Research 2016, 129:1-30. 10.1016/bs.acr.2015.08.001.
128. Vasko R.C., et al. Mechanistic studies of sansalvamide A-amide: An allosteric modulator of Hsp90. ACS Medicinal Chemistry Letters 2010, 1:4-8. 10.1021/ml900003t.
129. Walter S., Buchner J. Molecular chaperones-Cellular machines for protein folding. Angewandte Chemie, International Edition 2002, 41:1098-1113. 10.1002/1521-3773(20020402)41:7<1098::AID-ANIE1098>3.0.CO;2-9.
130. Wandinger S.K., Richter K., Buchner J. The Hsp90 chaperone machinery. Journal of Biological Chemistry 2008, 283:18473-18477. 10.1074/jbc.R800007200.
131. Wani M.C., Taylor H.L., Wall M.E., Coggon P., McPhail A.T. Plant antitumor agents. VI. Isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. Journal of the American Chemical Society 1971, 93:2325-2327. 10.1021/ja00738a045.
132. Wei W., et al. Novel celastrol derivatives inhibit the growth of hepatocellular carcinoma patient-derived xenografts. Oncotarget 2014, 5:5819-5831. 10.1016/j.bbagen.2014.06.008.
133. Westerheide S.D., et al. Celastrols as inducers of the heat shock response and cytoprotection. Journal of Biological Chemistry 2004, 279:56053-56060. 10.1074/jbc.M409267200.
134. Whitesell L., Bagatell R., Falsey R. The stress response: Implications for the clinical development of hsp90 inhibitors. Current Cancer Drug Targets 2003, 3:349-358.
135. Whitesell L., Lindquist S.L. HSP90 and the chaperoning of cancer. Nature Reviews. Cancer 2005, 5:761-772.
136. Workman P. Altered states: Selectively drugging the Hsp90 cancer chaperone. Trends in Molecular Medicine 2004, 10:47-51.
137. Xu W., Neckers L. Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells. Clinical Cancer Research 2007, 13:1625-1629. 10.1158/1078-0432.ccr-06-2966.
138. Yang H., Chen D., Cui Q.C., Yuan X., Dou Q.P. Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Research 2006, 66:4758-4765. 10.1158/0008-5472.CAN-05-4529.
139. Yang H., Shi G., Dou Q.P. The tumor proteasome is a primary target for the natural anticancer compound withaferin a isolated from "Indian winter cherry". Molecular Pharmacology 2007, 71:426-437. 10.1124/mol.106.030015.
140. Yi T., et al. Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling. Cancer Research 2008, 68:1843-1850. 10.1158/0008-5472.CAN-07-5944.
141. Yin Z., Henry E.C., Gasiewicz T.A. (-)-Epigallocatechin-3-gallate Is a novel Hsp90 inhibitor†. Biochemistry 2008, 48:336-345. 10.1021/bi801637q.
142. Yin Z., Henry E.C., Gasiewicz T.A. (-)-Epigallocatechin-3-gallate is a novel Hsp90 inhibitor. Biochemistry 2009, 48:336-345. 10.1021/bi801637q.
143. Yokota Y., Bargagna-Mohan P., Ravindranath P.P., Kim K.B., Mohan R. Development of withaferin A analogs as probes of angiogenesis. Bioorganic & Medicinal Chemistry Letters 2006, 16:2603-2607. doi:10.1016/j.bmcl.2006.02.039.
144. Young J.C., Agashe V.R., Siegers K., Hartl F.U. Pathways of chaperone-mediated protein folding in the cytosol. Nature Reviews. Molecular Cell Biology 2004, 5:781-791. 10.1038/nrm1492.
145. Yousuf S.K., et al. Ring A structural modified derivatives of withaferin A and the evaluation of their cytotoxic potential. Steroids 2011, 76:1213-1222. 10.1016/j.steroids.2011.05.012.
146. Yu X.M., et al. Hsp90 inhibitors identified from a library of novobiocin analogues. Journal of the American Chemical Society 2005, 127:12778-12779. 10.1021/ja0535864.
147. Yu Y., et al. Withaferin A targets heat shock protein 90 in pancreatic cancer cells. Biochemical Pharmacology 2010, 79:542-551. doi:10.1016/j.bcp.2009.09.017.
148. Zak F., et al. Platinum(IV) complex with adamantylamine as nonleaving amine group: Synthesis, characterization, and in vitro antitumor activity against a panel of cisplatin-resistant cancer cell lines. Journal of Medicinal Chemistry 2004, 47. 10.1021/jm030858+.
149. Zanphorlin L.M., Alves F.R., Ramos C.H. The effect of celastrol, a triterpene with antitumorigenic activity, on conformational and functional aspects of the human 90 kDa heat shock protein Hsp90alpha, a chaperone implicated in the stabilization of the tumor phenotype. Biochimica et Biophysica Acta 2014, 1840:3145-3152. 10.1016/j.bbagen.2014.06.008.
150. Zaveri N.T. Green tea and its polyphenolic catechins: Medicinal uses in cancer and noncancer applications. Life Sciences 2006, 78:2073-2080. doi:10.1016/j.lfs.2005.12.006.
151. Zhang T., et al. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Molecular Cancer Therapeutics 2008, 7:162-170. 10.1158/1535-7163.MCT-07-0484.
152. Zhang T., et al. Characterization of celastrol to inhibit hsp90 and cdc37 interaction. Journal of Biological Chemistry 2009, 284:35381-35389. 10.1074/jbc.M109.051532.
153. Zhang L., et al. Gambogic acid inhibits Hsp90 and deregulates TNF-α/NF-κB in HeLa cells. Biochemical and Biophysical Research Communications 2010, 403:282-287. doi:10.1016/j.bbrc.2010.11.018.
154. Zhao H., Brandt G.E., Galam L., Matts R.L., Blagg B.S. Identification and initial SAR of silybin: An Hsp90 inhibitor. Bioorganic and Medicinal Chemistry Letters 2011, 21:2659-2664. 10.1016/j.bmcl.2010.12.088.
155. Zhao H., Moroni E., Colombo G., Blagg B.S.J. Identification of a new scaffold for Hsp90 C-terminal inhibition. ACS Medicinal Chemistry Letters 2013, 5:84-88. 10.1021/ml400404s.
156. Zhao H., Reddy Kusuma B., Blagg B.S.J. Synthesis and evaluation of noviose replacements on novobiocin that manifest antiproliferative activity. ACS Medicinal Chemistry Letters 2010, 1:311-315. 10.1021/ml100070r.
157. Zhao Q., et al. Posttranscriptional regulation of the telomerase hTERT by gambogic acid in human gastric carcinoma 823 cells. Cancer Letters 2008, 262:223-231. 10.1016/j.canlet.2007.12.002.
158. Zhao H., et al. Engineering an antibiotic to fight cancer: Optimization of the novobiocin scaffold to produce anti-proliferative agents. Journal of Medicinal Chemistry 2011, 54:3839-3853. 10.1021/jm200148p.
159. Zhao J., et al. Triazole containing novobiocin and biphenyl amides as Hsp90 C-terminal inhibitors. Medicinal Chemistry Communications 2014, 5:1317-1323. 10.1039/C4MD00102H.
160. Zhao H., et al. Design, synthesis and biological evaluation of biphenylamide derivatives as Hsp90 C-terminal inhibitors. European Journal of Medicinal Chemistry 2015, 89:442-466. doi:10.1016/j.ejmech.2014.10.034.
161. Zhou Y.X., Huang Y.L. Antiangiogenic effect of celastrol on the growth of human glioma: An in vitro and in vivo study. Chinese Medical Journal 2009, 122:1666-1673.
162. Zuehlke A., Johnson J.L. Hsp90 and co-chaperones twist the functions of diverse client proteins. Biopolymers 2010, 93:211-217. 10.1002/bip.21292.